Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 5056  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1266    
    Printed26    
    Emailed0    
    PDF Downloaded46    
    Comments [Add]    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 7  |  Page : 17--24

Biomarkers in Migraine


1 Sidney Kimmel Medical College, Thomas Jefferson University, USA
2 Department of Neurology, Thomas Jefferson University, USA

Correspondence Address:
Dr. Stephanie J Nahas
Jefferson Headache Center, 90 0 Walnut Street, Suite 200, Philadelphia, PA 19107
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.315988

Rights and Permissions

Background: Disability from migraine has a profound impact on the world's economy. Research has been ongoing to identify biomarkers to aid in diagnosis and treatment. Objective: The aim of this study was to highlight the purported diagnostic and therapeutic migraine biomarkers and their role in precision medicine. Methods: A comprehensive literature search was conducted using PubMed, Google Scholar, and clinicaltrials.gov using keywords: “migraine” OR “headache” combined with “biomarkers” OR “marker.” Other keywords included “serum,” “cerebral spinal fluid,” “inflammatory,” and “neuroimaging.” Results: After a review of 88 papers, we find the literature supports numerous biomarkers in the diagnosis of migraine. Therapeutic biomarkers, while not as extensively published, highlight calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide-38 (PACAP-38) as biomarkers with the most substantiated clinical relevance. Genetic markers mainly focusing on gene mutations with resultant biochemical alterations continue to be studied and show promise. Conclusion: Although there are several proposed biomarkers for migraine, continued research is needed to substantiate their role in clinical practice.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow